UPDATE: Maxim Group Starts Reviva Pharmaceuticals (RVPH) at Buy, $10 PT

July 26, 2021 7:42 AM EDT
Get Alerts RVPH Hot Sheet
Price: $4.42 +1.38%

Rating Summary:
    1 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 5 | New: 36
Trade Now! 
Join SI Premium – FREE
(Updated - July 26, 2021 8:57 AM EDT)

Maxim Group analyst Jason McCarthy initiates coverage on Reviva Pharmaceuticals (NASDAQ: RVPH) with a Buy rating and a price target of $10.00. The analyst commented:

  • Reviva is developing its lead asset, RP5063, for the treatment of schizophrenia and respiratory indications including idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
  • RP5063 has a multimodal mechanism of action, more completely addressing the mix of positive, negative, and cognitive symptoms associated with schizophrenia.
  • The drug completed a P2 study (N=234) demonstrating robust efficacy in reducing the Positive and Negative Syndrome Scale (PANSS). On safety/tolerability, RP5063 demonstrated no signs of major side effects associated with antipsychotics like suicidal ideation or sexual dysfunction, and reported potentially best-in-class discontinuation rates.
  • RP5063 also delivered positive results in preclinical IPF/PAH models via its antagonist activity at key 5-HT receptors, which also has the potential to address major comorbid mental illnesses (e.g., depression and psychosis) in both IPF and PAH.
  • Conclusion. Current drugs for schizophrenia carry suboptimal efficacy and significant side effects, driving high discontinuation and relapse rates. RP5063 has a differentiated, multimodal approach validated by positive P2 data. At the current market cap of ~$66M and with P3 ahead and $35M in cash to fuel development, we view the risk/reward profile as favorable.

For an analyst ratings summary and ratings history on Reviva Pharmaceuticals click here. For more ratings news on Reviva Pharmaceuticals click here.

Shares of Reviva Pharmaceuticals closed at $3.83 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities

Maxim Group